The review by Onose et al. in this issue deals with neuroprotection. The authors state that recent studies, especially in the genetic, immune, histochemical and bio (nano)-technological fields, have provided new insight into the cellular and molecular mechanisms occurring within Central Nervous System (CNS)Fincluding Spinal cord injury (SCI). In their review, Onose et al. describe a newly emerging spectrum of therapies aiming to antagonize the 'secondary injury' pathways (i.e. to provide neuroprotection) and also to repair such classically irreparable structures. The authors also note that there have been identified many molecules, primarily expressed by heterogenous glial and neural subpopulations of cells, that are critical either directly or indirectly for tissue sparing, angiogenesis, neural plasticity and respectively, also, various substances/energy vectors with regenerative properties: MAG, OMgp, KDI, Nogo, NgR, the Rho signaling pathway, EphA4, GFAP, different subtypes of serotonergic and glutamatergic receptors, antigens, antibodies, immune modulators, adhesion molecules, scavengers, neurotrophic factors, enzymes, hormones, collagen scar inhibitors, remyelinating agents and neurogenetic/plasticity inducers, all aiming to preserve or re-establish the morphology and functional connections across the lesion site.
